Kidney cancer, characterized by the uncontrolled growth of malignant cells in the kidneys, is a significant global health challenge, with an estimated 400,000 new cases annually and nearly 175,000 deaths per year. The disease is commonly treated with first-line therapies, including immune checkpoint inhibitors and targeted therapies. However, a high unmet clinical need for more effective treatments remains, as current options often result in limited patient outcomes. The growing focus on immunotherapies, targeted treatments, and combination therapies is expected to drive the development of promising pipeline drugs, offering hope for improved survival rates and quality of life for patients in the future.
Report Coverage
The Advanced Kidney Cancer Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into advanced kidney cancer therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for advanced kidney cancer. The advanced kidney cancer report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The advanced kidney cancer pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with advanced kidney cancer treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to advanced kidney cancer.
Advanced Kidney Cancer Drug Pipeline Outlook
Advanced kidney cancer occurs when cancer cells grow uncontrollably in the kidneys, often spreading to other organs. It typically presents as clear-cell renal cell carcinoma (ccRCC), the most common form. Factors like smoking, obesity, and hypertension increase the risk of developing advanced kidney cancer. Early-stage cancers are treatable, but advanced stages are harder to manage, creating a significant clinical need for new therapies.
Advanced kidney cancer is primarily treated with targeted therapies, including tyrosine kinase inhibitors, and immune checkpoint inhibitors like nivolumab and pembrolizumab. Combination treatments, such as immunotherapy combined with targeted agents, are also increasingly used. These therapies aim to slow tumor growth and improve patient survival, addressing the significant unmet need for more effective treatment options in advanced stages.
Advanced Kidney Cancer Epidemiology
The advanced kidney cancer drug pipeline is crucial in addressing the increasing incidence of renal cell carcinoma, which affects approximately 9 individuals per 100,000 people annually in Spain. In the United States, approximately 81,800 new cases and 14,890 deaths from renal cell carcinoma and other kidney tumors were estimated in 2023. About 50% of cases are localized, while 25% are diagnosed with advanced or regional kidney cancer.
Advanced Kidney Cancer – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of advanced kidney cancer drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase I covers a major share of the total advanced kidney cancer clinical trials.
Advanced Kidney Cancer Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the advanced kidney cancer pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for advanced kidney cancer.
Advanced Kidney Cancer Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR report for the advanced kidney cancer report insights includes the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in advanced kidney cancer clinical trials:
- Bristol-Myers Squibb
- AstraZeneca
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Huabo Biopharm Co., Ltd.
- Chongqing Precision Biotech Co., Ltd.
- Osel, Inc.
- Pfizer
- NiKang Therapeutics, Inc.
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for advanced kidney cancer. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of advanced kidney cancer drug candidates.
Drug: TQB2450, Anlotinib, Sunitinib
The study, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., aims to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus sunitinib in patients with advanced renal cancer. This Phase 3 trial involves 528 participants and is expected to be completed by June 2025, with primary completion projected for December 2025.
Drug: Cabozantinib
The Phase II clinical trial sponsored by Emory University evaluates neoadjuvant cabozantinib for treating patients with locally advanced non-metastatic clear cell renal cell carcinoma before surgery. The primary objective is to assess the objective response rate following 12 weeks of treatment. The study is expected to be completed by February 2025 and has enrolled 22 participants.
Reasons To Buy This Report
The Advanced Kidney Cancer Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for advanced kidney cancer. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within advanced kidney cancer pipeline insights.
Key Questions Answered in the Advanced Kidney Cancer – Pipeline Insight Report
- What is the current landscape of advanced kidney cancer pipeline drugs?
- Which companies/institutions are developing advanced kidney cancer emerging drugs?
- How many phase II drugs are currently present in advanced kidney cancer pipeline drugs?
- Which company is leading the advanced kidney cancer pipeline development activities?
- What is the current advanced kidney cancer therapeutic assessment?
- What are the opportunities and challenges present in the advanced kidney cancer drug pipeline landscape?
- What is the efficacy and safety profile of advanced kidney cancer pipeline drugs?
- Which companies/institutions are involved in advanced kidney cancer collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in advanced kidney cancer?
Bladder Cancer Market Report
Global Clinical Trials Market
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Advanced Kidney Cancer
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Advanced Kidney Cancer
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Advanced Kidney Cancer: Epidemiology Snapshot
- 5.1 Advanced Kidney Cancer Incidence by Key Markets
- 5.2 Advanced Kidney Cancer – Patients Seeking Treatment in Key Markets
- 6 Advanced Kidney Cancer: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Advanced Kidney Cancer: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Advanced Kidney Cancer, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Advanced Kidney Cancer Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Advanced Kidney Cancer Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: TQB2450, Anlotinib, Sunitinib
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Biological: Nivolumab, Ipilimumab
- 10.2.3 Other Drugs
- 11 Advanced Kidney Cancer Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Drug: Cabozantinib
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: HB0025
- 11.2.3 Other Drugs
- 12 Advanced Kidney Cancer Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Biological: CD70 CAR-T cells
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Advanced Kidney Cancer Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Advanced Kidney Cancer, Key Drug Pipeline Companies
- 14.1 Bristol-Myers Squibb
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 AstraZeneca
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Huabo Biopharm Co., Ltd.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Chongqing Precision Biotech Co., Ltd.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 Osel, Inc.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Pfizer
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 NiKang Therapeutics, Inc.
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook